BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
COPD clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for chronic obstructive pulmonary disease: 198 (122 sponsors; 41 newly posted in the last 180 days, 9 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 16.9, rank 37 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 20, Phase 2 51, Phase 3 39, Phase 4 7, N/A 80.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Sanofi SNY | 12 | NA 3, P3 5, P2 1, P4 2, P1 1 | 4 | 1 |
| GlaxoSmithKline | 8 | P3 5, P1 2, P2 1 | 4 | 1 |
| AstraZeneca AZN | 17 | NA 10, P3 4, P4 2, P2 1 | 0 | 3 |
| Haisco Pharmaceutical Group Co., Ltd. | 7 | P2 4, P3 3 | 2 | 0 |
| Incyte Corporation INCY | 7 | NA 1, P3 3, P2 3 | 0 | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 4 | P3 2, P2 2 | 0 | 2 |
| Grifols Therapeutics LLC GRFS | 2 | P3 2 | 0 | 0 |
| Pfizer PFE | 2 | P3 2 | 1 | 0 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2 | P2 1, P3 1 | 0 | 0 |
| Hoffmann-La Roche | 2 | P3 1, P2 1 | 1 | 0 |
| Joincare Pharmaceutical Group Industry Co., Ltd | 2 | P2 1, P3 1 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 2 | P2 1, P3 1 | 1 | 0 |
| Regend Therapeutics | 2 | P3 1, EARLY_P1 1 | 1 | 0 |
| United Therapeutics UTHR new entrant | 2 | P3 1, P2 1 | 2 | 0 |
| Boehringer Ingelheim new entrant | 1 | P3 1 | 1 | 0 |
| Dompé Farmaceutici S.p.A | 1 | P3 1 | 0 | 1 |
| Enanta Pharmaceuticals, Inc ENTA new entrant | 1 | P3 1 | 1 | 0 |
| Eurofarma Laboratorios S.A. | 1 | P3 1 | 0 | 0 |
| Incyte Biosciences Japan GK INCY | 1 | P3 1 | 0 | 0 |
| Janssen Research & Development, LLC | 1 | P3 1 | 0 | 1 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | 1 | P3 1 | 0 | 0 |
| Fisher and Paykel Healthcare | 3 | NA 3 | 0 | 0 |
| Pulmair Medical, Inc. | 3 | NA 3 | 0 | 0 |
| Reistone Biopharma Company Limited | 3 | P1 2, P2 1 | 2 | 1 |
| Apreo Health, Inc. | 2 | NA 2 | 0 | 0 |
New-entrant sponsors: United Therapeutics, Boehringer Ingelheim, Enanta Pharmaceuticals, Inc.
Recently stopped trials
- NCT00662740 Boehringer Ingelheim - terminated: Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstruc
- NCT06603246 Genentech, Inc. - terminated: Sponsor's Decision A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
- NCT05292950 Arrowhead Pharmaceuticals - terminated: Sponsor business decision Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
- NCT07633314 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. - suspended: The sponsor has decided to suspend study progress. Further implementation of the study is pending notification. A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping®
- NCT07267130 Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. - terminated: This study shall be terminated as a result of strategic adjustments to the company-sponsored research and development of TQC3302 Inhalation A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy
- NCT00668772 Boehringer Ingelheim - terminated: Tiotropium/Salmeterol Inhalation Powder in COPD
- NCT04640025 Incyte Corporation - terminated: The decision to close the study was made due to the expiration of remaining drug supply. A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
- NCT07059273 Hoffmann-La Roche - withdrawn: The study was withdrawn due to a business decision. A COPD Data Registry for Participants With Frequent Exacerbations
- NCT03794583 United Therapeutics - terminated: Sponsor's decision Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | NCT06707883 A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | active not recruiting | 258 |
| 2026-12 est. | P2 | Connect Biopharm LLC CNTB | NCT07705737 Rademikibart IV for Acute Asthma and COPD Exacerbation | Asthma Acute; COPD Exacerbation Acute | recruiting | 40 |
| 2026-12-30 est. | P2 | Meribank Biotech Co., Ltd. | NCT06491043 Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells | Chronic Obstructive Pulmonary Disease | recruiting | 90 |
| 2027-02 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT07464587 Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | recruiting | 800 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07640451 A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | COPD | recruiting | 90 |
| 2026-09-30 est. | P2 | Joincare Pharmaceutical Group Industry Co., Ltd | NCT07351734 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD | COPD (Chronic Obstructive Pulmonary Disease) | recruiting | 120 |
| 2026-09-23 | P2 | Uniquity One (UNI) | NCT06496620 A Study to Evaluate Solrikitug in Participants With COPD (ZION) | COPD | active not recruiting | 182 |
| 2026-09-10 | P3 | Sanofi SNY | NCT06208306 A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | Chronic Obstructive Pulmonary Disease | completed | 669 |
| 2026-08-30 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07108699 Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) | active not recruiting | 180 |
| 2026-08-17 | P2 | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | NCT07016412 Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) | Chronic Obstructive Pulmonary Disease | completed | 497 |
| 2026-07-30 | P2 | Connect Biopharm LLC CNTB | NCT06940154 Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) | COPD Acute Exacerbation | completed | 159 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "chronic obstructive pulmonary disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.